Prostaglandins as a Topical Therapy for Erectile Dysfunction: A Comprehensive Review.


Journal

Sexual medicine reviews
ISSN: 2050-0521
Titre abrégé: Sex Med Rev
Pays: Netherlands
ID NLM: 101614773

Informations de publication

Date de publication:
01 10 2022
Historique:
received: 29 03 2022
accepted: 09 06 2022
medline: 14 4 2023
entrez: 13 4 2023
pubmed: 14 4 2023
Statut: ppublish

Résumé

Erectile dysfunction (ED) is a substantial cause of dissatisfaction among many men. This discontentment has led to the emergence of various drug treatment options for this problem. Unfortunately, due to various interactions, contraindications, and side effects, systemic therapies such as phosphodiesterase-5 inhibitors (including sildenafil, tadalafil, vardenafil, avanafil, etc.) are not welcomed in many patients. These problems have led researchers to look for other ways to reduce these complications. This article holistically reviews the efficacy of topical prostaglandins and their role in treating ED. We sought to provide a comprehensive overview of recent findings on the current topic by using the extensive literature search to identify the latest scientific reports on the topic. In this regard, topical and transdermal treatments can be suitable alternatives. In diverse studies, prostaglandins, remarkably PGE1 (also known as alprostadil), have been suggested to be an acceptable candidate for topical treatment. Numerous formulations of PGE1 have been used to treat patients so far. Still, in general, with the evolution of classical formulation methods toward modern techniques (such as using nanocarriers and skin permeability enhancers), the probability of treatment success also increases.

Identifiants

pubmed: 37051966
pii: 7016904
doi: 10.1016/j.sxmr.2022.06.004
doi:

Substances chimiques

Alprostadil F5TD010360
Prostaglandins 0
Sildenafil Citrate BW9B0ZE037
Phosphodiesterase 5 Inhibitors 0

Types de publication

Review Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

764-781

Informations de copyright

Copyright © 2022, International Society for Sexual Medicine. Published by Elsevier.

Déclaration de conflit d'intérêts

Conflicts of Interest: The authors declare that they have no competing interests.

Auteurs

Mohammadsadegh Hamzehnejadi (M)

Pharmaceutical Sciences and Cosmetic Products Research Center Kerman University of Medical Sciences, Kerman, Iran.

Marziye Ranjbar Tavakoli (MR)

Student Research Committee Kerman University of Medical Sciences, Kerman, Iran.

Fatemeh Homayouni (F)

Student Research Committee Kerman University of Medical Sciences, Kerman, Iran.

Zahra Jahani (Z)

Student Research Committee Kerman University of Medical Sciences, Kerman, Iran.

Masoud Rezaei (M)

Faculty of Medicine Kerman University of Medical Sciences, Kerman, Iran.

Mohammad Amin Langarizadeh (MA)

Pharmaceutical Sciences and Cosmetic Products Research Center Kerman University of Medical Sciences, Kerman, Iran.
Department of Medicinal Chemistry Faculty of Pharmacy Kerman University of Medical Sciences, Kerman, Iran.

Hamid Forootanfar (H)

Pharmaceutical Sciences and Cosmetic Products Research Center Kerman University of Medical Sciences, Kerman, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH